Welcome Newbies ! A few items you need to know as
Post# of 405
- This ticker (INNV) ran to 66 cents not that long ago on Fluti hype alone
- Full page advertising on virtually ALL top products (approx continues to happen in various small, medium, and large publications and newspapers around the country. Check it out (Bing.com and search Vesele ad / UriVarx ad etc)
- The original ANDA for Fluti is expected to be FDA approved by November as its still within usual time frames although on the longer end
- FlutiCare will be selling in Q4 2017 as they have side-stepped the continued long wait caused by FDA by going through a different APPROVED ANDA whereby Hikma is the manufacturer
- Profitabilty expected very soon as 1 full year of Fluti sales could fetch well North of $10M in revenue. Other combined INNV products likely to fetch 15-17M in revs so we could likely have a ~27M revenue based company exiting 2018. They just have to stay on the track they are already on. Have to ask yourself, what is their market cap today ?
- Expanding product presence in countries outside of USA...rapid pace
- Starting to leverage BH Platform info and stats to their advantage and will have product synergies like AllerVarx and FlutiCare which will enhance overall sales.
- Margins are over 75% (BH Platform / automatic reorders etc.)
- Q2 Earnings and CC after close on Monday 8/14 !
__________________HOW CAN U HELP ?________________________
Simple, Buy some product and tell 3 friends. Be a Product Ambassador and "talk up" our great products to those in need on popular HealthCare / Sports / Political forums, message boards, and social media sites ! #Act